![William Meury](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
William Meury
Directeur Général chez
INCYTE CORPORATION
Fortune : 16 M $ au 31/05/2026
Profil
William J.
Meury is Chief Executive Officer & Director at Incyte Corp.
since 2026.
He serves as Director at The Jed Foundation, Allergan Foundation, and International Council of Ophthalmology Foundation.
He is Senior Operating Advisor at Hildred Capital Management LLC since 2020.
Formerly, he was Chief Executive Officer & Director at Anthos Therapeutics, Inc. from 2024 to 2025.
He was President, Chief Executive Officer & Director at Karuna Therapeutics, Inc. from 2023 to 2024.
He was Chairman at Crown Laboratories, Inc. He was Independent Director at Syndax Pharmaceuticals, Inc. from 2018 to 2025.
He was Executive Vice President-Sales & Marketing at Forest Laboratories, Inc. from 2013 to 2014.
He was Chief Commercial Officer & Executive VP at Allergan UC from 2016 to 2020.
He was Senior Vice President-Sales at Forest Pharmaceuticals, Inc. from 1993 to 2014.
Education includes undergraduate studies at the University of Maryland.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
INCYTE CORPORATION 0,08 % | 15/04/2026 | 161 101 ( 0,08 % ) | 16 M $ | 31/05/2026 |
Postes actifs de William Meury
| Sociétés | Poste | Début |
|---|---|---|
| INCYTE CORPORATION | Directeur Général | 26/06/2025 |
The Jed Foundation
 The Jed Foundation Services to the Health IndustryHealth Services Engages in protecting and supporting emotional health and prevent suicide for nation's teens & young adults | Directeur/Membre du Conseil | - |
International Council of Ophthalmology Foundation | Directeur/Membre du Conseil | - |
Allergan Foundation | Directeur/Membre du Conseil | - |
Hildred Capital Management LLC
 Hildred Capital Management LLC Investment ManagersFinance Hildred Capital invests in middle market companies located in the United States with an enterprise value of USD 50 - 500 million and revenues of USD 10 - 100 million. The firm targets companies operating in the fields of healthcare services, consumer products, information technology, medical devices and pharmaceuticals products sectors. It provides financing for growth and buyout stage capital transactions with an investment size of USD 25 - 300 million. The firm also acquires majority and minority stake positions. | Consultant / Advisor | - |
Anciens postes connus de William Meury
| Sociétés | Poste | Fin |
|---|---|---|
| SYNDAX PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 24/06/2025 |
Anthos Therapeutics, Inc.
 Anthos Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops therapeutic options for the treatment of cardiovascular metabolic diseases | Directeur Général | 01/04/2025 |
| KARA THER | Directeur Général | 18/03/2024 |
| ALLERGAN PLC | Corporate Officer/Principal | 08/05/2020 |
| ░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░ ░ ░░░░░░░░░ | ░░░░░░░░░░ |
Formation de William Meury
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
56
Relations au 1er degré
13
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 13 |
|---|---|
Crown Laboratories, Inc.
 Crown Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets consumer skincare, prescription dermatology and aesthetic treatment products | Health Technology |
Forest Laboratories, Inc.
 Forest Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and sells drug products | Health Technology |
Incyte Corp.
 Incyte Corp. Pharmaceuticals: MajorHealth Technology Engages in discovery, development and commercialization of proprietary therapeutics | Health Technology |
Syndax Pharmaceuticals, Inc.
 Syndax Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company | Health Technology |
University of Maryland
 University of Maryland Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Forest Pharmaceuticals, Inc.
 Forest Pharmaceuticals, Inc. Forest ProductsNon-Energy Minerals Manufactures, distributes and sells forest-branded prescription products | Non-Energy Minerals |
International Council of Ophthalmology Foundation | |
The Jed Foundation
The Jed Foundation Services to the Health IndustryHealth Services Engages in protecting and supporting emotional health and prevent suicide for nation's teens & young adults | Health Services |
Allergan Ltd. (Ireland)
 Allergan Ltd. (Ireland) Pharmaceuticals: MajorHealth Technology Develops, manufactures and commercializes pharmaceuticals, devices, biological, surgical & regenerative medicine products | Health Technology |
Karuna Therapeutics, Inc.
 Karuna Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops medicines for psychiatric and neurological disorders like schizophrenia and Alzheimer’s disease | Health Technology |
Allergan Foundation | Health Services |
Hildred Capital Management LLC
Hildred Capital Management LLC Investment ManagersFinance Hildred Capital invests in middle market companies located in the United States with an enterprise value of USD 50 - 500 million and revenues of USD 10 - 100 million. The firm targets companies operating in the fields of healthcare services, consumer products, information technology, medical devices and pharmaceuticals products sectors. It provides financing for growth and buyout stage capital transactions with an investment size of USD 25 - 300 million. The firm also acquires majority and minority stake positions. | Finance |
Anthos Therapeutics, Inc.
Anthos Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops therapeutic options for the treatment of cardiovascular metabolic diseases | Health Technology |
